Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 8/2010

01-08-2010 | Original Article

Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma

Authors: Esther Kamphausen, Christiane Kellert, Tarish Abbas, Nadja Akkad, Stefan Tenzer, Graham Pawelec, Hansjoerg Schild, Peter van Endert, Barbara Seliger

Published in: Cancer Immunology, Immunotherapy | Issue 8/2010

Login to get access

Abstract

Immune surveillance of tumour cells by CD8+ cytotoxic T cells plays a key role in the establishment and control of an anti-tumour response. This process requires the generation of antigenic peptides, which are largely produced by the proteasome in combination with other proteases located in either the cytoplasm and/or the endoplasmic reticulum (ER). The ER-resident aminopeptidases ERAP1 and ERAP2 trim or even destroy HLA class I-binding peptides thereby shaping the peptide repertoire presented for T cell recognition. So far there exists limited information about the expression pattern of ERAP1 and/or ERAP2 in human tumours of distinct histotypes. Therefore, the expression profiles and modes of regulation of both aminopeptidases were determined in a large series of melanoma cell lines. A heterogeneous expression ranging from high to reduced or even total loss of ERAP1 and/or ERAP2 mRNA and/or protein expression was detected, which often could be induced/upregulated by interferon-γ treatment. The observed altered ERAP1 and/or ERAP2 expression and activity levels were either mediated by sequence alterations affecting the promoter or enzymatic activities, leading to either transcriptional and/or post-transcriptional downregulation mechanisms or limited or excessive processing activities, which both might have an impact on the antigenic peptide repertoire presented on HLA class I molecules.

Literature
  1. Jensen PE (2007) Recent advances in antigen processing and presentation. Nat Immunol 8:1041–1048View ArticlePubMed
  2. Yewdell JW (2005) The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 207:8–18View ArticlePubMed
  3. Hammer GE, Kanaseki T, Shastri N (2007) The final touches make perfect the peptide-MHC class I repertoire. Immunity 26:397–406View ArticlePubMed
  4. Goldberg AL, Cascio P, Saric T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147–164View ArticlePubMed
  5. Saveanu L, Carroll O, Hassainya Y, van Endert P (2005) Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation. Immunol Rev 207:42–59View ArticlePubMed
  6. Levy F, Burri L, Morel S et al (2002) The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J Immunol 169:4161–4171PubMed
  7. Endert P (2008) Role of tripeptidyl peptidase II in MHC class I antigen processing—the end of controversies. Eur J Immunol 38:609–613View ArticlePubMed
  8. Rock KL, York IA, Goldberg AL (2004) Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5:670–677View ArticlePubMed
  9. Stoltze L, Schirle M, Schwarz G et al (2000) Two new proteases in the MHC class I processing pathway. Nat Immunol 5:413–418View Article
  10. Hammer GE, Gonzalez F, James E, Nolla H, Shastri N (2007) In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat Immunol 8:101–108View ArticlePubMed
  11. Chang SC, Momburg F, Bhutani N, Goldberg AL (2006) The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci USA 102:17107–17112View Article
  12. Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N (2006) The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol 7:103–112View ArticlePubMed
  13. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848View ArticlePubMed
  14. Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69 Suppl 1:264–268View ArticlePubMed
  15. Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 118:129–138View ArticlePubMed
  16. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236View ArticlePubMed
  17. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197–206View ArticlePubMed
  18. Fruci D, Giacomini P, Nicotra MR et al (2008) Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol 216:742–749View ArticlePubMed
  19. Fruci D, Ferracuti S, Limongi MZ et al (2006) Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines. J Immunol 176:4869–4879PubMed
  20. Varona A, Blanco L, Lopez JI et al (2007) Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol Renal Physiol 292:F780–F788View ArticlePubMed
  21. Mehta AM, Jordanova ES, van Wezel T et al (2007) Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 46:577–586View ArticlePubMed
  22. Schatz MM, Peters B, Akkad N et al (2008) Characterizing the N-terminal processing motif of MHC class I ligands. J Immunol 180:3210–3217PubMed
  23. Reits E, Neijssen J, Herberts C et al (2004) A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20:495–506View ArticlePubMed
  24. Cui X, Rouhani FN, Hawari F, Levine SJ (2003) Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 171:6814–6819PubMed
  25. Akada T, Yamazaki T, Miyashita H et al (2002) Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is involved in the activation of endothelial integrins. J Cell Physiol 193:253–262View ArticlePubMed
  26. Shido F, Ito T, Nomura S et al (2006) Endoplasmic reticulum aminopeptidase-1 mediates leukemia inhibitory factor-induced cell surface human leukocyte antigen-G expression in JEG-3 choriocarcinoma cells. Endocrinology 147:1780–1788View ArticlePubMed
  27. Mehta AM, Jordanova ES, Corver WE et al (2009) Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer 48:410–418View ArticlePubMed
  28. Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B (1999) Gene transfer of the co-stimulatory molecules B7–1 and B7–2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 50:242–249View ArticlePubMed
  29. Herrmann F, Trowsdale J, Huber C, Seliger B (2003) Cloning and functional analyses of the mouse tapasin promoter. Immunogenetics 55:379–388View ArticlePubMed
  30. Atkins D, Ferrone S, Schmahl GE, Storkel S, Seliger B (2004) Downregulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma. J Urol 171:885–889View ArticlePubMed
  31. Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I et al (2001) Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61:8647–8650PubMed
  32. Kanaseki T, Blanchard N, Hammer GE, Gonzalez F, Shastri N (2006) ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulium. Immunity 25:795–806View ArticlePubMed
Metadata
Title
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma
Authors
Esther Kamphausen
Christiane Kellert
Tarish Abbas
Nadja Akkad
Stefan Tenzer
Graham Pawelec
Hansjoerg Schild
Peter van Endert
Barbara Seliger
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 8/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0856-7

Other articles of this Issue 8/2010

Cancer Immunology, Immunotherapy 8/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine